stockrowWhat it does
Oruka Therapeutics is a clinical-stage biotechnology company developing antibody medicines for psoriasis and other inflammatory diseases. Its predecessor was founded in 2024. Oruka has no products approved for commercial sale, so it is developing potential treatments rather than selling medicines today.
Its lead candidate, ORKA-001, is designed for psoriasis, a chronic autoimmune disease that can cause inflamed skin plaques. It targets IL-23p19, part of a signaling protein involved in inflammation. Oruka has engineered the antibody to remain in the body longer, with the aim of reducing how often patients need injections.
The co-lead candidate, ORKA-002, targets two related inflammatory proteins, IL-17A and IL-17F. Oruka is studying it for psoriasis and plans to study it for hidradenitis suppurativa, a skin disease that can cause painful nodules and abscesses. The company also identifies psoriatic arthritis, which affects skin and joints, as a potential indication.
Both lead candidates use half-life extension technology intended to increase their exposure in the body and decrease dosing frequency. Oruka also has a third program, ORKA-003, directed at an undisclosed pathway. Its development strategy applies antibody engineering to biological mechanisms already targeted by approved therapies.
How it makes money
Oruka has not generated revenue from product sales and does not expect product sales for several years, if at all. Its ability to generate enough product revenue to become profitable depends on successfully developing and commercializing its candidates. It has primarily funded operations through securities issuances, including preferred and common stock, a convertible note and pre-funded warrants.
ORKA-001 and ORKA-002 are its lead development programs. Oruka intends to test whether their extended half-lives can support less frequent injections than existing therapies. ORKA-001 is designed to support an injection as infrequently as once or twice per year; ORKA-002 is being studied for the potential of twice-yearly maintenance dosing in psoriasis. Neither schedule is an approved commercial regimen.
The company also plans a sequential regimen called ORKA-021, in which ORKA-002 would be followed by ORKA-001. ORKA-003 provides a possible route to other indications and combinations. These programs would need the relevant regulatory approvals before their products could be marketed.
Oruka has licensed rights to its lead programs from Paragon Therapeutics under royalty-bearing agreements. It expects to incur milestone, royalty or other payments under third-party license agreements. The company plans to establish sales, marketing and distribution infrastructure for products it may obtain approval to market itself. No commercial price or recurring product-sales stream is established in the information available here.
For the year ended December 31, 2025, Oruka reported a net loss of $105.4 million.
Customers and how it sells
Oruka’s intended patients include people with moderate-to-severe psoriasis. The ORKA-001 trials EVERLAST-A and EVERLAST-B and the ORKA-002 trial ORCA-SURGE are designed for patients with that form of the disease. Oruka also expects to study ORKA-002 in hidradenitis suppurativa and identifies psoriatic arthritis and other inflammatory conditions as potential uses.
The company has no approved products for commercial sale and has not generated product-sales revenue. It plans to establish sales, marketing and distribution infrastructure for any products it receives approval to market itself. For an approved product, reimbursement from government and other third-party payors is among the factors that could affect commercial success.
Oruka’s licenses from Paragon are worldwide. The ORKA-001 license covers certain antibodies and products targeting IL-23 outside inflammatory bowel disease; the ORKA-002 license covers certain antibodies and products targeting IL-17A/F in all fields. Oruka must obtain the required approvals in each country before conducting trials or marketing a product there. In some countries, a sales price must also be agreed or approved before launch.
Suppliers and costs
Paragon Therapeutics licenses Oruka the rights underlying ORKA-001 and ORKA-002 and works with Oruka on antibody engineering. The licenses are exclusive and royalty-bearing. Oruka also relies on third parties to develop its candidates and has established arrangements for manufacturing its programs and component materials.
The company’s primary use of cash is development of its candidates and pipeline. That includes research and development and the general and administrative expenses needed to support those operations. Oruka expects expenses to rise as it advances candidates into larger trials, increases manufacturing volumes, seeks approvals and potentially builds commercial infrastructure. It also expects payments under third-party license agreements.
For the year ended December 31, 2025, Oruka used $88.2 million in net cash for operating activities. It had 68 employees in FY2025. As of December 31, 2025, it had $479.6 million in cash, cash equivalents and marketable securities. Oruka expected those funds to support its operating plans for at least twelve months from the March 2026 filing date.
Competitive position
Oruka’s candidates would compete with approved medicines and treatments still in development. In psoriasis, approved IL-23 therapies include AbbVie’s Skyrizi and Janssen’s Tremfya; approved IL-17 therapies include UCB’s Bimzelx, Novartis’s Cosentyx and Eli Lilly’s Taltz. Amgen markets the oral medicine Otezla. Many competing therapies are also approved or in development for other inflammatory conditions that Oruka is targeting.
MoonLake Immunotherapeutics is developing sonelokimab, which targets IL-17A/F. AbbVie has announced plans to initiate a Phase 1 study of a long-acting IL-23p19 inhibitor in 2026. Oruka says efficacy, safety, convenience, price and reimbursement are among the factors likely to affect its candidates’ success if approved. Competitors also seek trial sites, patients, personnel and technologies.
Oruka’s lead candidates use licensed antibody rights and half-life extension technology. The company aims to reduce injection frequency while targeting mechanisms used by existing therapies.
Our reading: The exclusive Paragon licenses provide a basis for protecting access to the lead programs, but their scope is licensed rather than wholly owned, and Oruka says its ability to protect proprietary rights is uncertain. Our reading: Longer dosing intervals could differentiate the candidates, but the advantage remains unproven against established treatments and other candidates.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| AbbVie | Approved psoriasis biologics; developing a long-acting IL-23p19 inhibitor | High |
| Janssen | Approved IL-23 psoriasis biologics and an oral candidate | High |
| UCB | Approved IL-17A/F therapy for psoriasis and other conditions | High |
| Novartis | Approved IL-17 psoriasis therapy | High |
| Eli Lilly | Approved IL-17 psoriasis therapy and an oral candidate | High |
| Amgen | Approved biologic and oral psoriasis treatments | High |
| MoonLake Immunotherapeutics | IL-17A/F biologic in clinical development | Medium |
Growth opportunities
Oruka’s growth plans center on advancing its two lead antibodies, testing less frequent dosing and expanding into additional inflammatory diseases. In March 2026, the company expected to share Week 16 data for all EVERLAST-A patients in the second quarter of 2026 and longer-term data in the second half of 2026. It anticipated data from the ORKA-001 EVERLAST-B trial in 2027.
Oruka initiated ORCA-SURGE, a Phase 2 psoriasis trial of ORKA-002, in February 2026 and anticipated its data in 2027. The company also expected to initiate a Phase 2 trial in hidradenitis suppurativa in the second half of 2026. It plans to pursue ORKA-021, the sequential regimen of its two lead candidates, while ORKA-003 could support expansion beyond psoriasis.
Oruka estimates that the psoriasis pharmaceutical market had approximately $28 billion in annual global sales in 2024 and could grow to approximately $40 billion by 2032. Separately, it was reported on 26 October 2026 that an analyst estimated ORKA-001 could generate approximately $7.0 billion in peak global sales. That estimate is not product revenue achieved by Oruka.
Structural risks
- Clinical results and approval: Trials may fail to demonstrate safety or efficacy, produce inconclusive results or reveal undesirable side effects. Early clinical results may not predict later outcomes, and regulatory approval is costly and uncertain.
- Funding and losses: Oruka has incurred losses and expects substantial losses to continue. It will need additional financing for development and before a commercial drug can be produced, marketed and sold; inadequate financing could affect its operations.
- Third-party dependence: Oruka relies on third parties to develop its candidates and on licenses for a substantial portion of its portfolio, including the Paragon rights for both lead programs. It may also encounter manufacturing or quality-control difficulties.
- Competition and commercialization: Competitors may secure approval sooner, while Oruka’s candidates may fail to show meaningful improvements in efficacy or convenience. Product success would also depend on factors including price and reimbursement.
- Intellectual property: Oruka’s ability to obtain, maintain and protect patents and other proprietary rights is uncertain. It may fail to obtain or maintain rights needed for its programs.
Bottom line
Our reading
Oruka is a clinical-stage drug developer whose business depends on turning two licensed antibody programs into approved, commercially viable treatments. Its proposed differentiation is less frequent dosing against established inflammatory targets, but clinical and regulatory outcomes remain uncertain and approved competitors are already available. Its December 2025 cash position supports development, while the company expects continuing losses and a need for additional financing.